SCHEMBL28696167

SCHEMBL28696167

COc1ccc2nc(-c3ccccc3)cc(C(=O)Nc3ncc(-c4ccco4)[nH]3)c2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCL1 Q07820 9/20 0.55
▸ PLA2G2A P14555 2/20 0.54
▸ CA12 O43570 1/20 0.53
▸ CA1 P00915 1/20 0.53
▸ CA2 P00918 1/20 0.53
▸ CA9 Q16790 1/20 0.53
▸ TACR3 P29371 1/20 0.52
▸ CYP3A4 P08684 1/20 0.51
▸ APOBEC3A P31941 1/20 0.50
▸ APOBEC3G Q9HC16 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ UBE2I P63279 2/20 0.49
▸ CACNA1B Q00975 2/20 0.49
▸ APBA1 Q02410 2/20 0.49
▸ SAE1 Q9UBE0 2/20 0.49
▸ UBA2 Q9UBT2 2/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ STAT3 P40763 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28673422 0.92 MEN1 (0.59) MCL1TACR3CYP3A4APOBEC3AAPOBEC3G
SCHEMBL28931754 0.91 MEN1 (0.59) MCL1CYP3A4APOBEC3AAPOBEC3GTDP1
SCHEMBL28672796 0.89 MCL1 (0.46) MCL1PLA2G2ACACNA1BAPBA1STAT3
SCHEMBL28681436 0.88 STAT3 (0.61) MCL1CYP3A4APOBEC3AAPOBEC3GTDP1
SCHEMBL28680477 0.85 MCL1 (0.57) MCL1STAT3
SCHEMBL28673390 0.84 MCL1 (0.65) MCL1
SCHEMBL28683183 0.83 CHEK1 (0.58) MCL1CYP3A4APOBEC3AAPOBEC3GTDP1
SCHEMBL28680486 0.83 KDM4E (0.58) CA12CA1CA2CA9CYP3A4
SCHEMBL28695985 0.82 STAT3 (0.55) MCL1CYP3A4APOBEC3AAPOBEC3GTDP1
SCHEMBL28699093 0.82 CTDSP1 (0.62) MCL1TACR3APOBEC3AAPOBEC3GTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113747920-A Immune checkpoint inhibitor combination therapy using quinoline carboxamide derivatives 株式会社益力多本社 2021-12-03 — — CN disclosed
CN-112703001-A Combination cancer therapy using quinoline carboxamide derivatives 株式会社益力多本社 2021-04-23 — — CN disclosed
Send feedback